1. Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie. 1995;26:83-99.

2. Amoros M, Lurton E, Boustie J, et al. Comparison of the anti-herpes simplex virus activities of propolis and 3-methylbut-2-enyl caffeate. J Nat Prod. 1994;57(5):644-647.

3. Iwu M, Duncan A, Okunji C. Dietary botanical supplements with antiviral and anti-inflammatory properties used in the treatment of liver disorders in traditional African medicine. Complementary and Alternative Medicine in Chronic Liver Disease Conference. National Institues of Health. Bethesda, Maryland. 1999.

4. Rice-Evans CA, Miller NJ, Paganga G. Stucture-antioxidant relationships of flavonoids and phenolic acids. Free Radic Biol Med. 1996;20(7):933-956.

5. Katamaya T. Hypolipemic action of phytic acid (IP6): prevention of fatty liver. Anticancer Res. 1999;19(5A):3695-3698.

6. Patney NL, Pachori S. A study of serum glycolytic enzymes and serum B hepatitis in relation to Liv.52 therapy. The Medicine and Surgery. 1986(XXVI);4:9.

7. Chawhan, RN, Talib SH, Talib VH, et al.Viral hepatitis in children. The Medicine and Surgery 1976; 3, 9. [Note: This information was provided by an herb manufacturer, but is not available through the National Library of Medicine's database PubMed.]

8. Mukerjee AB, Dasgupta M. Cirrhosis of liver. Results of treatment with an indigenous drug Liv.52. J Ind Med Prof. 1971; 12:7853.

9. Fleig WW, Morgan MY, Hölzer MA. The ayurvedic drug LIV.52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial [Abstract]. a European multicenter study group. J Hepatol. 1997;26(Suppl 1):127.

10. Fujisawa K, Suzuki H, Yamamoto S, et al. Therapeutic effects of liver hydrolysate preparation on chronic hepatitis - A double blind, controlled study. Asian Med J. 1984;26:497-526.

11. Sanbe K, Murata T, Fujisawa K, et al. Treatment of liver disease - with particular reference to liver hydrolysates. Jap J Clin Exp Med. 1973;50:2665-76.

12. Kidd P. Phosphatidylcholine: a superior protectant against liver damage. Altern Med Rev. 1996;1(4):258-274.

13. Freidman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD, (Eds.). Hepatology: A Textbook of Liver Disease. WB Saunders. Phildelphia, Pennsylvania. 1996:791-833.

14. Kahlon JB, Kemp MC, Yawel N, et al. In vitro evaluation of the synergistic antiviral effects of acemannin in combination with azidothymidine and acyclovir. Mol Biother. 1991;3(4):214-23.

15. Womble E, et al. The impact of acemannan on the generation and function of cytotoxic T-lymphocytes. Immunopharm. 1992;14:3-67.

16. Kelly G. Larch arabinogalactan. Clinical relevance of a novel immune-enhancing polysaccharide. Altern Med Rev. 1999;4(2):96-103.

17. Sweeney BF, McDaniel CF. Glyconutritional and phytochemicals in eight HCV-positive patients. Proceedings of the Fisher Institute for Medical Research. 1999;1(3):6-7.

18. Ghoneum M, Jewett A. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2. Cancer Detect Prev. 2000;24(4):314-324.

19. Jacoby HL, Wonorowski G, Sakata K, et al. The effect of MGN-3 on cisplatin and adriamycin induced toxicity in the rat. Gastroenterology. 2000;118(4):4962. [Note: This information is not available through the National Library of Medicine's database PubMed, but a synopsis of the article was available at the time of publication at: www.jafra.gr.jp/sis-e.html.

20. Csatary LK, Moss RW, Beuth J, et al. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Research. 1999;19(1B):629-634.

21. Csatary LK, Telegdy L, Gergely P, Bodey B, Bakacs T. Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res. 1998;18(2B):1279-1282.

22. Csatary LK, Schnabel R, Bakacs, T. Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anticancer Res. 1999;19(1B):629-633.

23. Stauder G, Kabil S. Oral enzyme therapy in hepatitis C patients. Int J Immunother. 1997; XIII (3/4):153-158. [Note: This information was provided by the product manufacturer, but is not available through the National Library of Medicine's database PubMed.]

24. Beardsley T, Hayes SM. Induction of T-cell maturation by a cloned line of thymic epithelium (TEPI). Proc Nat Acad Sci USA. 1983;80(19):6005-6009.

25. Riordan NH, Jackson JA, Riordan HD. A pilot study on the effects of thymus protein on elevated Epstein-Barr virus titers in human subjects. Project RECNAC Wichita State University. Townsend Letter for Doctors. 1998;175:78-89. [Note: This information was provided by the product manufacturer, but is not available through the National Library of Medicine's database PubMed.]

26. Sherman KE, Sjorem M, Creager RL, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. 1998;27(4):1128-1135.

27. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Eng J Med. 1987;316(6):297-303.

28. Olney RC. Treatment of viral hepatitis with the Knott technic of blood irradiation. Am J Surgery. 1959;90:402-409.